Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Qiagen N.V.
  6. News
  7. Summary
    QGEN   NL0012169213


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

QIAGEN N.V. Reaffirms Effectiveness of SARS-CoV-2 PCR Tests in Light of the New Coronavirus Variant B.1.1.529

11/26/2021 | 09:18am EST

QIAGEN N.V. announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the emergence of a new variant of concern detected in South Africa. QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against the genetic mutations of the variant, which is known by its scientific name, B.1.1.529. The assessment was made against data available in the GISAID and GenBank public databases. This applies to all of QIAGEN?s PCR tests for detection of the SARS-CoV-2 virus involving: artus SARS-CoV-2 Prep&Amp UM Kit, a CE-marked SARS-CoV-2 test that integrates sample preparation and detection in a single kit, enabling throughput of more than 670 tests per PCR cycler in an eight-hour shift QIAstat-Dx syndromic testing system, which includes the CE-marked test QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 to quickly identify in about an hour whether patients have common seasonal respiratory infections or SARS-CoV-2. QIAGEN also offers the offers the QIAstat-Dx Respiratory+ test in the U.S., Europe and other markets for detection of more than 20 respiratory illnesses, including COVID-19 infections. NeuMoDx 96 and 288 integrated PCR testing systems used in laboratory testing. QIAGEN offers tests worldwide for use on this system for detection of the SARS-CoV-2 virus. In the U.S., the NeuMoDx Flu A-B/RSV/SARS-CoV-2 VantageAssay is available for use in testing patients with suspect infections. Furthermore, the new variant is reliably detected by: company?s QIAcuity digital PCR solution, which uses a SARS-CoV-2 wastewater surveillance assay developed in collaboration with GT Molecular Inc. QIAGEN?s QIAprep& Viral RNA kit, which uses qPCR genotyping assays that are available in collaboration with biomers.net. QIAGEN has been closely monitoring ? and will continue to do so ? the performance of its PCR tests as new variants emerge in the global fight against the coronavirus pandemic. Surveillance of genetic variations will continue on a biweekly basis. The new variant of concern joins a list of other variants with potentially increased transmissibility. These include the Alpha variant (B.1.1.7, first detected in the United Kingdom), the Beta variant (B.1.351, identified in South Africa), and the Gamma variant (B.1.1.28 P1, detected in Brazil). As a virus encoded by RNA nucleotides, SARS-CoV-2 frequently mutates due to erroneous or ineffective replication of the virus genome. These mutations can sometimes produce viruses with altered properties or even entirely new strains. To better identify and differentiate potentially dangerous variants, countries around the world are increasing the frequency of sequencing positive SARS-CoV-2 samples to monitor the occurrence of potential mutations. To support these initiatives, QIAGEN offers the QIAseq DIRECT SARS-CoV-2 solution for rapid and comprehensive monitoring of sequence drift of the virus around the world, as well as QIAGEN Digital Insights bioinformatic analysis solutions.

ę S&P Capital IQ 2021
All news about QIAGEN N.V.
01/19Qiagen N.V Launched Higher on M&A Chatter
01/19QIAGEN N : supports young biotechnology and pharma companies by announcing winners of firs..
01/19QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021
01/18QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products
01/18QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products
01/18DZ Bank Upgrades Qiagen to Buy from Hold, Raises Price Target to $59.34 From $55.79
01/17ANALYST RECOMMENDATIONS : Admiral, Hiscox, National Grid, Qiagen, Unilever...
01/17QIAGEN NV : DZ Bank takes a positive view
01/13QIAGEN N : liquid-based sample-prep-and-detection kit helps labs ramp up COVID testing cap..
01/10QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIA..
More news
Analyst Recommendations on QIAGEN N.V.
More recommendations
Financials (USD)
Sales 2021 2 198 M - -
Net income 2021 473 M - -
Net Debt 2021 941 M - -
P/E ratio 2021 23,7x
Yield 2021 -
Capitalization 11 254 M 11 254 M -
EV / Sales 2021 5,55x
EV / Sales 2022 5,71x
Nbr of Employees 6 000
Free-Float 97,8%
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 49,57 $
Average target price 57,79 $
Spread / Average Target 16,6%
EPS Revisions
Managers and Directors
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Vice President-Finance
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
QIAGEN N.V.-12.85%11 304
MODERNA, INC.-31.46%70 577
LONZA GROUP AG-14.10%53 088
IQVIA HOLDINGS INC.-14.84%45 903
SEAGEN INC.-14.26%24 238